Stay updated with breaking news from Lexaria Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
DehydraTECH delivers equivalent quantity of oral THC three times faster: 15 minutes vs. 45 minutesKELOWNA, BC / ACCESSWIRE / October 13, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the
DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controlsPeak levels achieved were up to 10x higher than controlsKELOWNA, BC / ACCESSWIRE / October 5, 2021 / Lexaria Bioscience
11th Annual PODD Drug Delivery Conference Announces 2021 Keynotes The Conference Forum is pleased to announce that the 11th annual PODD: Partnership Opportunities in Drug Delivery conference will take place in-person on October 28-29, 2021, at The Westin Boston Seaport District in Boston, MA. PODD brings together the R&D industry and the drug delivery community to figure out the best routes of delivering therapeutics and reducing the burden to patients. PODD 2021 kicks off with Barbara Lueckel, PhD, Global Head of Research Technologies Partnering, Roche Pharma Partnering, followed by Dr Rob...
Lexaria Announces 2021 Annual Meeting Results ACCESSWIRE 30 Jun 2021, 06:19 GMT+10 KELOWNA, BC / ACCESSWIRE / June 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the 'Company' or 'Lexaria'), a global innovator in drug delivery platforms announces the results of the 2021 Annual Meeting (the 'Meeting'). On June 28, 2021 at 1:00 p.m. (Pacific Time), the Company held the Meeting whereby there were 2,735,413 shares of the Company represented in person or by proxy at the meeting, constituting 53.6% of the Company's issued share capital as at May 3, 2021, being the record ...
Lexaria Bioscience Corp.: Lexaria Provides Progress Report on Six R&D Programs All studies are using DehydraTECH 2.0 formulations for multiple market applications, including antivirals, hypertension, NSAIDs and oral nicotine These studies are part of Lexaria's 2021 applied R&D program intended to enable opportunities for strategic partnerships KELOWNA, BC / ACCESSWIRE / June 9, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this progress report on several studies within its 2021 appli...